FDA sends Fresenius new warning letter; P&G CEO got big boost as he exited; Statins to hold onto market;

@FiercePharma: Merck has the Zilmax PR right: Animal advocate Temple Grandin to consult on livestock drug's safety. More | Follow @FiercePharma

@EricPFierce: Regeneron takes a "byte" out of excess manufacturing capacity in Ireland. ICYMI yesterday | Follow @EricPFierce

@CarlyHFierce: Amid Purdue criticism, CVS cuts opioid access for 'risky' prescribers. ICYMI yesterday | Follow @CarlyHFierce

> Germany's Fresenius said today that it is addressing issues raised by the FDA in a warning letter about a blood bag manufacturing facility in Puerto Rico. Report

> A new study says the market for drugs to treat dyslipidemia will reach $31 billion in 2022 and that statins will remain the biggest sellers, despite work on new treatments. Story

> SBI Pharmaceuticals is striking a deal in Bahrain to open a manufacturing facility to produce diabetes and cancer drugs. Report

> The FDA is looking more closely at the accuracy of consumer blood glucose testing. Report (reg. req.)

> Lupin has gotten FDA approval to make a generic of Sanofi's ($SNY) tuberculosis drug Rifadin. Item

Medical Device News

@FierceMedDev: Bard settles vaginal mesh suit as thousands pend. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Israel's InSightec is expanding into Canada with its surgery-free uterine fibroid treatment. News | Follow @DamianFierce

@MarkHFierce: We're launching a new diagnostics report in less than a week, and I'll be writing it. Sign up here | Follow @MarkHFierce

@MichaelGFierce: FDA clears Novo Nordisk's insulin injection pen for children. Item | Follow @MichaelGFierce

> FDA's guidance for wireless devices sparks business opportunity. More

> KKR, Bain said to bid for Panasonic's billion-dollar health unit. Article

> A first: Medtronic co-founder absent from annual meeting. Item

Biotech News

@FierceBiotech: Shire and Santaris extend their strategic alliance to discover, develop LNA-drugs in the rare disease field. Press release | Follow @FierceBiotech

@JohnCFierce: The latest on the Onyx buyout: Yes they are. No they aren't. Say what? Item | Follow @JohnCFierce

@EmilyMFierce: This week's career moves in biopharma. Chutes & Ladders | Follow @EmilyMFierce

> GlaxoSmithKline ponders future of Crohn's disease drug after PhIII flop. Report

> 3-D printing creates living tissue cells, holds promise for medical research. Story

> Vical restructures, chops 47 jobs after PhIII immunotherapy flop. Article

> Mystery doc cited for handing insider trial info to SAC trader. Report

And Finally... Procter & Gamble ($PG), which has a significant OTC joint venture with Teva Pharmaceutical Industries ($TEVA), today acknowledged paying a $3.3 million bonus in 2013 to former CEO Bob McDonald, who stepped down in May amid disappointing sales by the company. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.